Compare ARK Genomic Revolution ETF (ARKG) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Freeport-McMoRan Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.26, while Freeport-McMoRan Inc trades at $61.49 (market cap $88.44B). The key difference: Freeport-McMoRan Inc pays a 0.98% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Freeport-McMoRan Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | FCX | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $71.73 |
52-Week Low | $23.09 | $35.34 |
Market Cap | — | $88.44B |
Enterprise Value | — | $95.10B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
FCX trades at $61.52, up 1.69% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.60. Revenue growth is steady, and profitability metrics like a 10.34% net income margin and 14.7% ROE reflect operational strength. Recent news highlights FCX's role in the copper market, driven by AI and energy transition demand.
The outlook is positive due to robust copper demand and expansion projects, but risks include commodity price volatility and high debt. Analysts are bullish with a $73.35 consensus price target, implying 19% upside. Investors should weigh strong cash flows and dividend payments against cyclical industry exposure and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
